Evidence map›Paper›PMID 25160795›Full record

ReviewCurrent psychiatry reports2014

Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments.

Jennifer N Vega, Paul A Newhouse

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current psychiatry reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study.Journal of cancer survivorship : research and practice · 2019
    Trial
  13. A Robotic Coach Architecture for Elder Care (ROCARE) Based on Multi-User Engagement Models.IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society · 2017
    Trial
  14. Trial
  15. Perspectives from Alzheimer's Disease Research Centers site directors on the early steps and the lasting impact.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jennifer N VegaCenter for Cognitive Medicine, Department of Psychiatry, Vanderbilt University School of Medicine, 1601 23rd Ave. S., Nashville, TN, 37212, USA.
Paul A Newhouse

Funding

Estrogen Effects on Cholinergic Function in Older WomenR01AG021476 · NIA · VANDERBILT UNIVERSITY · PI NEWHOUSE, PAUL A. · 2003 to 2013
$4.2M
Training Program on Genetic Variation and Human PhenotypesT32GM080178 · NIGMS · VANDERBILT UNIVERSITY · PI COX, NANCY J, SAMUELS, DAVID C · 2007 to 2021
$3.1M
NIA NIH HHS R01 AG021476NIGMS NIH HHS T32 GM080178
6 · The paper itself

Abstract

Mild cognitive impairment (MCI) is widely regarded as the intermediate stage of cognitive impairment between the changes seen in normal cognitive aging and those associated with dementia. Elderly patients with MCI constitute a high-risk population for developing dementia, in particular Alzheimer's disease (AD). Although the core clinical criteria for MCI have remained largely unchanged, the operational definition of MCI has undergone several revisions over the course of the last decade and remains an evolving diagnosis. Prognostic implications of this diagnosis are becoming clearer with regard to the risk of progressive cognitive deterioration. Although patients with MCI may represent an optimal target population for pharmacological and non-pharmacological interventions, results from clinical trials have been mixed and an effective treatment remains elusive. This article provides a brief overview of the evolution of the concept of MCI and reviews current diagnostic criteria, the longitudinal course of the disorder, and current and emerging treatments for MCI.

Indexed as

Cognitive DysfunctionCholinesterase InhibitorsClinical Trials as TopicCognitionCognitive Behavioral TherapyExerciseHumansNeuroprotective AgentsPrognosisVitaminsCholinesterase InhibitorsNeuroprotective AgentsVitamins

Identifiers

PMID25160795
PMCPMC4169219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.